Physician profile
Matthew Dickson
NPI 1528021706
$6,960.14
in general payments reported to CMS, 2019-2025
21 companies · $1,240 in 2025
The $1,240 reported for 2025 was more than what 85% of Otolaryngology/Facial Plastic Surgery providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $959 · 2020: $797 · 2021: $1,061 · 2022: $551 · 2023: $619 · 2024: $1,735 · 2025: $1,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,269 · Travel and Lodging: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,268.69 |
| Travel and Lodging | $324.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $1,896.53 | 2019-2024 | Acclarent Aera, Trudi Nav Cable, Acclarent Navwire |
| Intersect Ent, INC. | $1,073.58 | 2019-2022 | |
| Inspire Medical Systems, INC. | $899.30 | 2023-2024 | Inspire |
| Integra Lifesciences Corporation | $790.04 | 2024-2025 | Trudi Probe, Inspira Air, Acclarent Aera |
| Glaxosmithkline, LLC. | $456.93 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $381.68 | 2023-2025 | |
| Aerin Medical INC. | $363.17 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $254.85 | 2022-2025 | Dupixent |
| Optinose US, INC. | $200.73 | 2019-2025 | |
| Stryker Corporation | $165.98 | 2019-2023 | Xpress Ent Dilation System |
| Medtronic, INC. | $138.24 | 2022 | |
| Genentech USA, INC. | $68.96 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $64.52 | 2019-2025 | Airsupra |
| Amgen INC. | $52.01 | 2025 | Tezspire |
| Smith+Nephew, INC. | $44.27 | 2019-2023 | Ent Sinus, Coblation, Tula |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $22.90 | 2021 | |
| Shire North American Group INC | $19.81 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.47 | 2019 | |
| Paratek Pharmaceuticals, INC. | $18.36 | 2025 | Xhance |
| Novartis Pharmaceuticals Corporation | $17.33 | 2019 | |
| Baxter Healthcare | $12.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Dickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.